Hutchinson–Gilford progeria syndrome (HGPS) causes premature aging in children, with adipose tissue, skin and bone deterioration, and cardiovascular impairment. In HGPS cells and mouse models, high levels of interleukin-6, an inflammatory cytokine linked to aging processes, have been detected. Here, we show that inhibition of interleukin-6 activity by tocilizumab, a neutralizing antibody raised against interleukin-6 receptors, counteracts progeroid features in both HGPS fibroblasts and LmnaG609G/G609G progeroid mice. Tocilizumab treatment limits the accumulation of progerin, the toxic protein produced in HGPS cells, rescues nuclear envelope and chromatin abnormalities, and attenuates the hyperactivated DNA damage response. In vivo administration of tocilizumab reduces aortic lesions and adipose tissue dystrophy, delays the onset of lipodystrophy and kyphosis, avoids motor impairment, and preserves a good quality of life in progeroid mice. This work identifies tocilizumab as a valuable tool in HGPS therapy and, speculatively, in the treatment of a variety of aging-related disorders.

Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice / Squarzoni S.; Schena E.; Sabatelli P.; Mattioli E.; Capanni C.; Cenni V.; D'Apice M.R.; Andrenacci D.; Sarli G.; Pellegrino V.; Festa A.; Baruffaldi F.; Storci G.; Bonafe M.; Barboni C.; Sanapo M.; Zaghini A.; Lattanzi G.. - In: AGING CELL. - ISSN 1474-9718. - ELETTRONICO. - 20:1(2021), pp. e13285.13285-e13285.13301. [10.1111/acel.13285]

Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice

Sarli G.;Pellegrino V.;Bonafe M.;Barboni C.;Sanapo M.;Zaghini A.;
2021

Abstract

Hutchinson–Gilford progeria syndrome (HGPS) causes premature aging in children, with adipose tissue, skin and bone deterioration, and cardiovascular impairment. In HGPS cells and mouse models, high levels of interleukin-6, an inflammatory cytokine linked to aging processes, have been detected. Here, we show that inhibition of interleukin-6 activity by tocilizumab, a neutralizing antibody raised against interleukin-6 receptors, counteracts progeroid features in both HGPS fibroblasts and LmnaG609G/G609G progeroid mice. Tocilizumab treatment limits the accumulation of progerin, the toxic protein produced in HGPS cells, rescues nuclear envelope and chromatin abnormalities, and attenuates the hyperactivated DNA damage response. In vivo administration of tocilizumab reduces aortic lesions and adipose tissue dystrophy, delays the onset of lipodystrophy and kyphosis, avoids motor impairment, and preserves a good quality of life in progeroid mice. This work identifies tocilizumab as a valuable tool in HGPS therapy and, speculatively, in the treatment of a variety of aging-related disorders.
2021
Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice / Squarzoni S.; Schena E.; Sabatelli P.; Mattioli E.; Capanni C.; Cenni V.; D'Apice M.R.; Andrenacci D.; Sarli G.; Pellegrino V.; Festa A.; Baruffaldi F.; Storci G.; Bonafe M.; Barboni C.; Sanapo M.; Zaghini A.; Lattanzi G.. - In: AGING CELL. - ISSN 1474-9718. - ELETTRONICO. - 20:1(2021), pp. e13285.13285-e13285.13301. [10.1111/acel.13285]
Squarzoni S.; Schena E.; Sabatelli P.; Mattioli E.; Capanni C.; Cenni V.; D'Apice M.R.; Andrenacci D.; Sarli G.; Pellegrino V.; Festa A.; Baruffaldi F.; Storci G.; Bonafe M.; Barboni C.; Sanapo M.; Zaghini A.; Lattanzi G.
File in questo prodotto:
File Dimensione Formato  
IL6-AgingCell.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.46 MB
Formato Adobe PDF
2.46 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/795517
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 26
social impact